Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Efficacy returned 22 record(s)
|
|
Monday, 07/30/2018
|
Efficacy of 'the Islands'-Based Projects Compared to Student-Collected Data Projects in Introductory Statistics Courses
Ryne VanKrevelen, Elon University; Kirsten Doehler, Elon University; Andrea Metts, Elon University; Lisa Rosenberg, Elon University; Laura Taylor, Elon University
|
Efficacy of 'the Islands'-Based Projects Compared to Student-Collected Data Projects in Introductory Statistics Courses
Ryne VanKrevelen, Elon University; Kirsten Doehler, Elon University; Andrea Metts, Elon University; Lisa Rosenberg, Elon University; Laura Taylor, Elon University
9:10 AM
|
A Hybrid Method for the Stratified Mark-Specific Proportional Hazards Models with Missing Data, with Applications to Dengue Vaccine Efficacy Trials
Yanqing Sun, University of North Carolina At Charlotte; Li Qi, Biostatistics and Programming, Sanofi; Peter Gilbert, Fred Hutchinson Cancer Research Center; Fei Heng, University of North Carolina at Charlotte
9:15 AM
|
A Unified Approach to the Statistical Evaluation of Differential Vaccine Efficacy
Erin Gabriel, Karolinska Institute; Dean Follmann, NIAID
11:20 AM
|
Epidemiological Modeling to Guide Efficacy Study Design Evaluating Vaccines to Prevent Emerging Diseases
An Vandebosch, Janssen; Joris Menten, Janssen ; Guillermo Herrera-Taracena, Janssen
11:35 AM
|
Are Tumor Size Changes Predictive of Survival for Immunotherapy Trials?
Meihua Wang, Merck & Co.; Thomas Jemielita, Merck & Co.; Cong Chen, Merck & Co.; Chen Hu, Johns Hopkins University
2:35 PM
|
Evaluation of Regional Efficacy Equivalence in Developing Biosimilars
Ryuji Uozumi, Kyoto University Graduate School of Medicine; Shinjo Yada, A2 Healthcare Corporation
3:20 PM
|
|
Tuesday, 07/31/2018
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
|
The Myth of Making Inference for Overall Treatment Efficacy with Data from Multiple Studies via Meta-Analysis
Brian Claggett, Harvard Medical School
8:55 AM
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
9:10 AM
|
Choosing the Primary Efficacy Analysis for a Randomized Clinical Trial with Competing Risks
Eric Leifer, National Heart, Lung, and Blood Institute; James Troendle, National Institutes of Health; Lauren Kunz, National Heart, Lung, and Blood Institute
2:05 PM
|
General Regression Model for the Subdistribution of a Competing Risk Under Left-Truncation and Right-Censoring
Anna Bellach, Fred Hutch Cancer Research Center; Michael Kosorok, University of North Carolina at Chapel Hill; Peter Gilbert, Fred Hutchinson Cancer Research Center; Jason P Fine, University of North Carolina at Chapel Hill
2:35 PM
|
|
Wednesday, 08/01/2018
|
Statistical Models for Longitudinal Analysis of Preclinical Efficacy Screens
William Forrest, Genentech, Inc; Bruno Alicke, Genentech; Oleg Mayba, Genentech; Alice Starr, Genentech
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
Statistical Models for Longitudinal Analysis of Preclinical Efficacy Screens
William Forrest, Genentech, Inc; Bruno Alicke, Genentech; Oleg Mayba, Genentech; Alice Starr, Genentech
8:45 AM
|
Assessing Pharmacokinetic Marker Correlates of a Failure Time Outcome, with Application to HIV Prevention Efficacy Trials
Peter Gilbert, Fred Hutchinson Cancer Research Center; Lily Zhang, Fred Hutchinson Cancer Research Center; Erika Thommes, Fred Hutchinson Cancer Research Center; Yunda Huang, Fred Hutchinson Cancer Research Center
9:35 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
A Comparison of Statistical Models for Recurrent Events with Applications to Hospitalization and Death Events
Jihong Chen, Alnylam Pharmaceuticals; Tim Lin, Alnylam Pharmaceuticals; Matthew T. White, Alnylam Pharmaceuticals; Christine Powell, Alnylam Pharmaceuticals; Andrew Strahs, Alnylam Pharmaceuticals
11:05 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
Adaptive Dose Finding in Oncology Phase I-II Studies with Consideration of Tolerability and Efficacy
Rachael Liu, Takeda Pharmaceuticals ; Ling Wang, Takeda; David Sinclair, Google; Jianchang Lin, Takeda Pharmaceuticals
11:35 AM
|
Propensity Score Methods for Efficacy Comparison in the Lack of Randomization
Qing Li, University of Iowa; Guang Chen, Celgene Corp.
11:50 AM
|
|
|
